Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2247562,
author = {Behrens, F. and Taylor, P. C. and Wetzel, D. and Brun, N. C. and BrandtandJuergens, J. and Drescher, E. and Dokoupilová, Eva and RowinskaandOsuch, A. and Martin, N. AbdelandKader and de Vlam, K.},
doi = {http://dx.doi.org/10.1136/annrheumdis-2022-eular.536},
keywords = {Izokibep; ABY-035; psoriatic arthriris; clinical trial},
language = {eng},
title = {IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY},
url = {https://ard.bmj.com/content/81/Suppl_1/170},
year = {2022}
}
TY - CONF
ID - 2247562
AU - Behrens, F. - Taylor, P. C. - Wetzel, D. - Brun, N. C. - Brandt-Juergens, J. - Drescher, E. - Dokoupilová, Eva - Rowinska-Osuch, A. - Martin, N. Abdel-Kader - de Vlam, K.
PY - 2022
TI - IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
KW - Izokibep
KW - ABY-035
KW - psoriatic arthriris
KW - clinical trial
UR - https://ard.bmj.com/content/81/Suppl_1/170
N2 - Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogenous musculoskeletal manifestation (arthritis, spondylitis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and nail psoriasis). In addition, PsA is commonly associated with comorbidities such as metabolic syndrome and cardiovascular diseases where IL-17 is a key driver of this disease. Izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution. Here, we report 16-week phase 2 results in patients with active PsA.
ER -
BEHRENS, F., P. C. TAYLOR, D. WETZEL, N. C. BRUN, J. BRANDT-JUERGENS, E. DRESCHER, Eva DOKOUPILOVÁ, A. ROWINSKA-OSUCH, N. Abdel-Kader MARTIN a K. DE VLAM. \textit{IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY}. 2022. ISSN~0003-4967. Dostupné z: https://dx.doi.org/10.1136/annrheumdis-2022-eular.536.
|
